FDA approves new test for CHD biomarker: low LDL levels. (coronary heart disease, low density lipoprotein).(Cardiovascular Medicine)(Brief Article)
Publication: Internal Medicine News
Publication Date: 15-OCT-03
Author: Franklin, Deeanna
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The Food and Drug Administration has granted marketing clearance for the PLAC test, which measures blood levels of lipoprotein-associated phospholipase A2.
Blood levels of this macrophage-produced enzyme are elevated in people with coronary heart disease (CHD). PLAC test results are expected to help predict CHD risk in patients-with normal...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
